VOXEL SA ZY 1

Research VOXEL SA ZY 1 (0NX) on Bullrun: market cap EUR 299.32M, P/E 3.3, dividend yield 3.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 299.32M; P/E is 3.3; dividend yield is 3.7%.

Peer valuation comparison

Latest P/E is 3.29x versus a Healthcare sector median of 23.83x (86.2% below).

Latest dividend yield is 3.72% versus a Healthcare sector median of 2.17% (71.4% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 583.79MEUR 98.53MEUR 40.87M28.8%n/aEUR 13.02MEUR 185.65MEUR 408.90M
FY2022n/aPLN 45.62Mn/an/a4230PLN 33.17MPLN 20.67MPLN 243.91M
FY2021n/aPLN 71.71Mn/an/a6720PLN 54.15MPLN 32.77MPLN 230.53M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-07-30EUR 299.32M3.32.1%0.59

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.59 EUR, yield 3.7%.

YearDividends/share
FY20220.71 PLN
FY20210.47 PLN

About VOXEL SA ZY 1

Voxel S.A. provides medical services in Poland. The company offers imaging diagnostics services, including reimbursed, commercial, and private patient examinations; teleradiology services; and clinical/pharmaceutical trials. It is also involved in the sale of radiopharmaceuticals, and the leasing of land. Voxel S.A. was incorporated in 2005 and is headquartered in Kraków, Poland.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is VOXEL SA ZY 1's market cap?

VOXEL SA ZY 1's market capitalization is EUR 299.32M.

What is VOXEL SA ZY 1's P/E ratio?

VOXEL SA ZY 1's price-to-earnings (P/E) ratio is 3.3.

Does VOXEL SA ZY 1 pay a dividend?

VOXEL SA ZY 1 has a dividend yield of 3.7%.

What does VOXEL SA ZY 1 do?

Voxel S.A. provides medical services in Poland. The company offers imaging diagnostics services, including reimbursed, commercial, and private patient examinations; teleradiology services; and clinical/pharmaceutical trials. It is also involved in the sale of radiopharmaceuticals, and the leasing of land. Voxel S.A. was incorporated in 2005 and is headquartered in Kraków, Poland.